Physician profile
Mark E Mckeigue
NPI 1962480657
$3,550.52
in general payments reported to CMS, 2019-2025
31 companies · $84.32 in 2025
The $84.32 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $859 · 2020: $336 · 2021: $496 · 2022: $717 · 2023: $706 · 2024: $352 · 2025: $84.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,142.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $652.68 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $580.03 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $465.19 | 2021-2024 | |
| Astrazeneca Pharmaceuticals Lp | $226.62 | 2022-2023 | Breztri |
| Amarin Pharma, INC. | $216.08 | 2019-2020 | |
| Pfizer INC. | $151.48 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $146.78 | 2019 | |
| Aimmune Therapeutics, INC. | $124.99 | 2024 | |
| Allergan, INC. | $118.59 | 2019-2020 | |
| Corcept Therapeutics | $94.07 | 2022-2025 | Korlym |
| Vanda Pharmaceuticals INC. | $84.76 | 2020-2022 | |
| Abbott Laboratories | $73.09 | 2023 | Freestyle Libre 3 |
| Biohaven Pharmaceuticals, INC. | $66.21 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $65.94 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.21 | 2020-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.10 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $51.45 | 2021-2022 | |
| Boston Scientific Corporation | $46.17 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.56 | 2021-2022 | |
| Glaxosmithkline, LLC. | $32.18 | 2019-2021 | |
| Sanofi Pasteur INC. | $32.06 | 2022 | |
| Idorsia Pharmaceuticals US INC | $25.27 | 2022-2023 | Quviviq |
| Merck Sharp & Dohme LLC | $22.63 | 2024 | Capvaxive, Gardasil, Gardasil 9 |
| Exact Sciences Corporation | $17.08 | 2023 | Cologuard Collection Kit |
| Phadia US INC. | $15.38 | 2022 | |
| Currax Pharmaceuticals LLC | $15.30 | 2024 | Contrave, Onzetra Xsail |
| Ethicon US, LLC | $14.91 | 2019 | |
| Amgen INC. | $14.53 | 2023 | Evenity, Prolia |
| Hologic Sales and Service, LLC | $13.97 | 2020 | |
| Baxter Healthcare | $12.92 | 2021 | |
| Esperion Therapeutics, INC. | $12.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Mckeigue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.